Concepts (309)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ovarian Neoplasms | 11 | 2026 | 415 | 2.950 |
Why?
|
| Anti-Bacterial Agents | 6 | 2026 | 432 | 2.440 |
Why?
|
| Neoplasm Recurrence, Local | 8 | 2026 | 154 | 2.430 |
Why?
|
| Endometrial Neoplasms | 9 | 2025 | 79 | 1.840 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2026 | 220 | 1.480 |
Why?
|
| Genital Neoplasms, Female | 5 | 2022 | 17 | 1.380 |
Why?
|
| Cystadenocarcinoma, Serous | 3 | 2022 | 44 | 1.200 |
Why?
|
| Uterine Neoplasms | 2 | 2017 | 53 | 0.950 |
Why?
|
| Surgical Wound Infection | 1 | 2024 | 22 | 0.840 |
Why?
|
| Female | 50 | 2026 | 24698 | 0.780 |
Why?
|
| Aged | 28 | 2026 | 8214 | 0.780 |
Why?
|
| Carcinoma, Endometrioid | 3 | 2021 | 20 | 0.760 |
Why?
|
| Humans | 67 | 2026 | 43102 | 0.730 |
Why?
|
| Infertility | 1 | 2022 | 21 | 0.730 |
Why?
|
| Middle Aged | 33 | 2026 | 12222 | 0.720 |
Why?
|
| Retrospective Studies | 11 | 2026 | 2544 | 0.720 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2020 | 25 | 0.650 |
Why?
|
| Community Health Services | 4 | 2017 | 206 | 0.610 |
Why?
|
| Community-Based Participatory Research | 6 | 2024 | 352 | 0.610 |
Why?
|
| Neoplasm Staging | 9 | 2025 | 374 | 0.600 |
Why?
|
| Residence Characteristics | 3 | 2018 | 363 | 0.600 |
Why?
|
| Violence | 2 | 2018 | 136 | 0.600 |
Why?
|
| Poverty | 3 | 2016 | 400 | 0.510 |
Why?
|
| Cohort Studies | 7 | 2024 | 1759 | 0.500 |
Why?
|
| Adult | 27 | 2026 | 13872 | 0.490 |
Why?
|
| Renal Insufficiency, Chronic | 4 | 2019 | 193 | 0.490 |
Why?
|
| Medically Uninsured | 2 | 2016 | 65 | 0.480 |
Why?
|
| Community-Institutional Relations | 3 | 2017 | 219 | 0.480 |
Why?
|
| Breast Neoplasms | 5 | 2022 | 1723 | 0.450 |
Why?
|
| Albuminuria | 2 | 2012 | 78 | 0.430 |
Why?
|
| Myometrium | 1 | 2014 | 17 | 0.420 |
Why?
|
| Lymph Nodes | 1 | 2014 | 74 | 0.410 |
Why?
|
| Peritoneal Neoplasms | 2 | 2024 | 18 | 0.410 |
Why?
|
| Urban Health Services | 1 | 2014 | 44 | 0.410 |
Why?
|
| Cisplatin | 3 | 2024 | 98 | 0.410 |
Why?
|
| Immunotherapy | 2 | 2025 | 144 | 0.400 |
Why?
|
| Multilingualism | 1 | 2014 | 52 | 0.400 |
Why?
|
| Neoplasms | 5 | 2015 | 1377 | 0.370 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2026 | 307 | 0.370 |
Why?
|
| Cooperative Behavior | 3 | 2014 | 269 | 0.370 |
Why?
|
| Los Angeles | 9 | 2023 | 394 | 0.350 |
Why?
|
| SEER Program | 3 | 2017 | 164 | 0.340 |
Why?
|
| Kidney Failure, Chronic | 1 | 2012 | 242 | 0.330 |
Why?
|
| Survival Rate | 4 | 2021 | 355 | 0.320 |
Why?
|
| Health Knowledge, Attitudes, Practice | 6 | 2015 | 989 | 0.310 |
Why?
|
| Health Status Disparities | 4 | 2015 | 719 | 0.300 |
Why?
|
| Organizational Case Studies | 1 | 2008 | 31 | 0.280 |
Why?
|
| Uterine Cervical Neoplasms | 3 | 2024 | 367 | 0.280 |
Why?
|
| Mass Screening | 1 | 2012 | 541 | 0.280 |
Why?
|
| Prognosis | 7 | 2025 | 861 | 0.260 |
Why?
|
| Quality of Health Care | 1 | 2008 | 161 | 0.260 |
Why?
|
| Patient Care Management | 1 | 2006 | 5 | 0.260 |
Why?
|
| Social Welfare | 1 | 2006 | 29 | 0.250 |
Why?
|
| Interdisciplinary Communication | 1 | 2006 | 40 | 0.250 |
Why?
|
| Models, Cardiovascular | 1 | 2007 | 98 | 0.250 |
Why?
|
| Long-Term Care | 2 | 2022 | 55 | 0.240 |
Why?
|
| Peritoneum | 1 | 2025 | 9 | 0.240 |
Why?
|
| Male | 24 | 2020 | 23409 | 0.230 |
Why?
|
| Disease Progression | 2 | 2026 | 667 | 0.230 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2025 | 53 | 0.220 |
Why?
|
| Fallopian Tube Neoplasms | 1 | 2024 | 5 | 0.220 |
Why?
|
| Early Detection of Cancer | 3 | 2020 | 449 | 0.220 |
Why?
|
| DNA Mismatch Repair | 2 | 2025 | 28 | 0.220 |
Why?
|
| Health Education | 1 | 2008 | 363 | 0.220 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2024 | 9 | 0.210 |
Why?
|
| Clinical Medicine | 1 | 2004 | 7 | 0.210 |
Why?
|
| Health Services | 1 | 2004 | 61 | 0.210 |
Why?
|
| Venous Thromboembolism | 1 | 2024 | 22 | 0.210 |
Why?
|
| Incidence | 3 | 2024 | 1078 | 0.210 |
Why?
|
| Medicaid | 2 | 2007 | 143 | 0.210 |
Why?
|
| Neoadjuvant Therapy | 2 | 2020 | 23 | 0.210 |
Why?
|
| Young Adult | 8 | 2020 | 5080 | 0.200 |
Why?
|
| Health Services Research | 1 | 2004 | 161 | 0.200 |
Why?
|
| Neoplastic Stem Cells | 1 | 2024 | 99 | 0.200 |
Why?
|
| Aged, 80 and over | 8 | 2025 | 2853 | 0.190 |
Why?
|
| Clinical Trials as Topic | 3 | 2025 | 259 | 0.190 |
Why?
|
| Histones | 1 | 2024 | 197 | 0.190 |
Why?
|
| Progesterone Reductase | 1 | 2022 | 1 | 0.190 |
Why?
|
| Steroid Isomerases | 1 | 2022 | 2 | 0.190 |
Why?
|
| United States | 8 | 2025 | 5205 | 0.190 |
Why?
|
| Chromatin | 1 | 2024 | 186 | 0.190 |
Why?
|
| Adipokines | 1 | 2022 | 28 | 0.190 |
Why?
|
| Risk Assessment | 5 | 2021 | 863 | 0.190 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2025 | 220 | 0.190 |
Why?
|
| Proportional Hazards Models | 3 | 2021 | 518 | 0.190 |
Why?
|
| Lymphatic Metastasis | 3 | 2022 | 81 | 0.190 |
Why?
|
| Alopecia | 1 | 2022 | 11 | 0.190 |
Why?
|
| Cell Nucleus | 1 | 2024 | 383 | 0.190 |
Why?
|
| Multienzyme Complexes | 1 | 2022 | 69 | 0.190 |
Why?
|
| Disinfection | 1 | 2022 | 10 | 0.180 |
Why?
|
| Infection Control | 1 | 2022 | 18 | 0.180 |
Why?
|
| Cross-Sectional Studies | 6 | 2023 | 3156 | 0.180 |
Why?
|
| Adolescent | 9 | 2020 | 6081 | 0.180 |
Why?
|
| Cross Infection | 1 | 2022 | 48 | 0.180 |
Why?
|
| Insurance Coverage | 2 | 2016 | 110 | 0.170 |
Why?
|
| Genitalia, Female | 1 | 2021 | 29 | 0.170 |
Why?
|
| Diabetes Mellitus | 2 | 2019 | 539 | 0.170 |
Why?
|
| Vaccines | 1 | 2022 | 65 | 0.170 |
Why?
|
| Cardiovascular Diseases | 2 | 2007 | 749 | 0.170 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2020 | 19 | 0.160 |
Why?
|
| Drug Interactions | 1 | 2021 | 150 | 0.160 |
Why?
|
| Cyclophosphamide | 1 | 2020 | 59 | 0.160 |
Why?
|
| Models, Statistical | 1 | 2021 | 195 | 0.160 |
Why?
|
| Comprehensive Health Care | 1 | 2019 | 11 | 0.160 |
Why?
|
| Medical Record Linkage | 1 | 2019 | 17 | 0.160 |
Why?
|
| Antibodies, Protozoan | 1 | 2020 | 82 | 0.150 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2019 | 7 | 0.150 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 1067 | 0.150 |
Why?
|
| Postoperative Complications | 1 | 2021 | 263 | 0.150 |
Why?
|
| Telemedicine | 1 | 2023 | 234 | 0.150 |
Why?
|
| Health Personnel | 1 | 2022 | 277 | 0.150 |
Why?
|
| Chagas Disease | 1 | 2020 | 104 | 0.150 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2007 | 760 | 0.140 |
Why?
|
| Midwestern United States | 1 | 2018 | 21 | 0.140 |
Why?
|
| Disease Models, Animal | 1 | 2024 | 1596 | 0.140 |
Why?
|
| Electronic Health Records | 1 | 2019 | 108 | 0.140 |
Why?
|
| Risk | 2 | 2021 | 287 | 0.140 |
Why?
|
| Developing Countries | 2 | 2009 | 113 | 0.140 |
Why?
|
| Patient Selection | 2 | 2021 | 205 | 0.140 |
Why?
|
| Neoplasm Invasiveness | 2 | 2020 | 290 | 0.130 |
Why?
|
| Mental Disorders | 1 | 2022 | 392 | 0.130 |
Why?
|
| Allostasis | 1 | 2017 | 25 | 0.130 |
Why?
|
| Attitude of Health Personnel | 1 | 2019 | 231 | 0.130 |
Why?
|
| Risk Factors | 6 | 2024 | 3994 | 0.130 |
Why?
|
| Religion | 1 | 2017 | 90 | 0.120 |
Why?
|
| Sex Factors | 2 | 2018 | 1028 | 0.120 |
Why?
|
| Pregnancy | 1 | 2022 | 1772 | 0.120 |
Why?
|
| Chicago | 1 | 2016 | 31 | 0.120 |
Why?
|
| Qualitative Research | 2 | 2017 | 574 | 0.120 |
Why?
|
| Perception | 2 | 2015 | 215 | 0.120 |
Why?
|
| Social Class | 2 | 2016 | 291 | 0.120 |
Why?
|
| Mortality | 1 | 2017 | 175 | 0.120 |
Why?
|
| Vulnerable Populations | 1 | 2017 | 166 | 0.120 |
Why?
|
| Research Subjects | 1 | 2015 | 35 | 0.110 |
Why?
|
| Disease-Free Survival | 2 | 2025 | 116 | 0.110 |
Why?
|
| Pitch Discrimination | 1 | 2014 | 4 | 0.110 |
Why?
|
| Voice | 1 | 2014 | 5 | 0.110 |
Why?
|
| Health Behavior | 3 | 2015 | 575 | 0.100 |
Why?
|
| Feedback, Physiological | 1 | 2014 | 32 | 0.100 |
Why?
|
| Delphi Technique | 1 | 2014 | 34 | 0.100 |
Why?
|
| Healthcare Disparities | 3 | 2015 | 590 | 0.100 |
Why?
|
| Tumor Burden | 1 | 2014 | 84 | 0.100 |
Why?
|
| Trust | 1 | 2015 | 167 | 0.100 |
Why?
|
| San Francisco | 2 | 2023 | 35 | 0.100 |
Why?
|
| Models, Neurological | 1 | 2014 | 136 | 0.100 |
Why?
|
| Program Development | 1 | 2014 | 240 | 0.100 |
Why?
|
| Language | 1 | 2014 | 185 | 0.090 |
Why?
|
| HIV Infections | 1 | 2006 | 2586 | 0.090 |
Why?
|
| Registries | 3 | 2020 | 437 | 0.090 |
Why?
|
| Health Status | 1 | 2016 | 442 | 0.090 |
Why?
|
| Age Factors | 4 | 2020 | 1154 | 0.090 |
Why?
|
| Cerebral Cortex | 1 | 2014 | 306 | 0.090 |
Why?
|
| Chronic Disease | 3 | 2016 | 549 | 0.090 |
Why?
|
| Nutrition Assessment | 1 | 2012 | 80 | 0.090 |
Why?
|
| Time Factors | 1 | 2016 | 1857 | 0.090 |
Why?
|
| Acupuncture Therapy | 1 | 2011 | 12 | 0.090 |
Why?
|
| Feeding Behavior | 2 | 2012 | 469 | 0.080 |
Why?
|
| Health Promotion | 1 | 2017 | 704 | 0.080 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2010 | 16 | 0.080 |
Why?
|
| Hypertension | 3 | 2019 | 835 | 0.080 |
Why?
|
| Fatigue | 1 | 2011 | 100 | 0.080 |
Why?
|
| Internet | 1 | 2012 | 236 | 0.080 |
Why?
|
| Universities | 1 | 2014 | 559 | 0.080 |
Why?
|
| Self Care | 1 | 2011 | 175 | 0.080 |
Why?
|
| Patient Education as Topic | 1 | 2011 | 235 | 0.080 |
Why?
|
| Quality of Life | 1 | 2014 | 616 | 0.070 |
Why?
|
| Snake Bites | 1 | 2009 | 2 | 0.070 |
Why?
|
| Zoonoses | 1 | 2009 | 21 | 0.070 |
Why?
|
| Prospective Studies | 2 | 2025 | 1600 | 0.070 |
Why?
|
| Leptospirosis | 1 | 2009 | 31 | 0.070 |
Why?
|
| Creatinine | 1 | 2008 | 102 | 0.070 |
Why?
|
| Case Management | 1 | 2008 | 24 | 0.070 |
Why?
|
| Biomedical Research | 1 | 2014 | 502 | 0.070 |
Why?
|
| Health Surveys | 2 | 2008 | 405 | 0.070 |
Why?
|
| Consensus | 1 | 2008 | 48 | 0.070 |
Why?
|
| Education | 1 | 2008 | 60 | 0.070 |
Why?
|
| Socioeconomic Factors | 4 | 2015 | 1234 | 0.070 |
Why?
|
| Stress, Psychological | 1 | 2014 | 661 | 0.070 |
Why?
|
| Cell Line, Tumor | 2 | 2024 | 2676 | 0.060 |
Why?
|
| Food Supply | 1 | 2008 | 122 | 0.060 |
Why?
|
| Feasibility Studies | 2 | 2021 | 259 | 0.060 |
Why?
|
| Insurance, Health | 1 | 2007 | 145 | 0.060 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2025 | 32 | 0.060 |
Why?
|
| Animals | 5 | 2024 | 16992 | 0.060 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2006 | 226 | 0.050 |
Why?
|
| Antihypertensive Agents | 1 | 2007 | 287 | 0.050 |
Why?
|
| Capital Financing | 1 | 2004 | 2 | 0.050 |
Why?
|
| Medical Oncology | 1 | 2024 | 50 | 0.050 |
Why?
|
| Body Mass Index | 3 | 2015 | 925 | 0.050 |
Why?
|
| Gene Deletion | 1 | 2005 | 168 | 0.050 |
Why?
|
| Cadherins | 1 | 2005 | 102 | 0.050 |
Why?
|
| Education, Medical, Continuing | 1 | 2004 | 35 | 0.050 |
Why?
|
| Methylation | 1 | 2024 | 119 | 0.050 |
Why?
|
| Fellowships and Scholarships | 1 | 2004 | 32 | 0.050 |
Why?
|
| Internal Medicine | 1 | 2004 | 32 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2020 | 375 | 0.050 |
Why?
|
| Prevalence | 3 | 2019 | 1612 | 0.050 |
Why?
|
| Teaching | 1 | 2004 | 59 | 0.050 |
Why?
|
| Public Health | 1 | 2008 | 424 | 0.050 |
Why?
|
| Taxes | 1 | 2023 | 14 | 0.050 |
Why?
|
| Forecasting | 1 | 2004 | 136 | 0.050 |
Why?
|
| Water Supply | 1 | 2023 | 60 | 0.050 |
Why?
|
| Protein Transport | 1 | 2024 | 296 | 0.050 |
Why?
|
| Cities | 1 | 2023 | 79 | 0.050 |
Why?
|
| Paclitaxel | 1 | 2023 | 64 | 0.050 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2024 | 347 | 0.050 |
Why?
|
| Child | 2 | 2022 | 3443 | 0.050 |
Why?
|
| Androgen Antagonists | 1 | 2022 | 29 | 0.050 |
Why?
|
| Adiponectin | 1 | 2022 | 59 | 0.050 |
Why?
|
| Neoplasm, Residual | 1 | 2022 | 17 | 0.050 |
Why?
|
| Stomach Neoplasms | 1 | 2005 | 241 | 0.050 |
Why?
|
| Patients' Rooms | 1 | 2022 | 1 | 0.050 |
Why?
|
| Fomites | 1 | 2022 | 3 | 0.050 |
Why?
|
| Disinfectants | 1 | 2022 | 8 | 0.050 |
Why?
|
| Mice | 2 | 2024 | 6644 | 0.050 |
Why?
|
| Health Facilities | 1 | 2022 | 32 | 0.040 |
Why?
|
| Androgens | 1 | 2022 | 106 | 0.040 |
Why?
|
| New York | 1 | 2022 | 93 | 0.040 |
Why?
|
| Leptin | 1 | 2022 | 118 | 0.040 |
Why?
|
| Ultraviolet Rays | 1 | 2022 | 118 | 0.040 |
Why?
|
| Risk-Taking | 2 | 2015 | 457 | 0.040 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2021 | 21 | 0.040 |
Why?
|
| Adenosine Triphosphate | 1 | 2022 | 206 | 0.040 |
Why?
|
| Prostatic Neoplasms | 1 | 2010 | 1092 | 0.040 |
Why?
|
| Gastrointestinal Diseases | 1 | 2021 | 51 | 0.040 |
Why?
|
| Hysterectomy | 1 | 2020 | 38 | 0.040 |
Why?
|
| Gastrointestinal Tract | 1 | 2021 | 71 | 0.040 |
Why?
|
| Bolivia | 1 | 2020 | 9 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2022 | 321 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2021 | 341 | 0.040 |
Why?
|
| Seroepidemiologic Studies | 1 | 2020 | 74 | 0.040 |
Why?
|
| Patient Care Team | 1 | 2020 | 60 | 0.040 |
Why?
|
| Endometrium | 1 | 2020 | 59 | 0.040 |
Why?
|
| Vaccination | 1 | 2022 | 355 | 0.040 |
Why?
|
| Lymph Node Excision | 1 | 2019 | 25 | 0.040 |
Why?
|
| Gynecology | 1 | 2019 | 35 | 0.040 |
Why?
|
| Causality | 2 | 2009 | 45 | 0.040 |
Why?
|
| Brazil | 2 | 2009 | 84 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2020 | 458 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2021 | 719 | 0.040 |
Why?
|
| Trypanosoma cruzi | 1 | 2020 | 157 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 1 | 2020 | 526 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 1081 | 0.030 |
Why?
|
| Mental Health | 1 | 2022 | 385 | 0.030 |
Why?
|
| DNA Methylation | 1 | 2020 | 403 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2017 | 107 | 0.030 |
Why?
|
| Rural Population | 1 | 2020 | 373 | 0.030 |
Why?
|
| Cause of Death | 1 | 2017 | 186 | 0.030 |
Why?
|
| Infant | 1 | 2020 | 1175 | 0.030 |
Why?
|
| Comorbidity | 2 | 2009 | 737 | 0.030 |
Why?
|
| Environment Design | 1 | 2016 | 32 | 0.030 |
Why?
|
| Diet | 2 | 2012 | 826 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2024 | 1019 | 0.030 |
Why?
|
| Marketing of Health Services | 1 | 2015 | 8 | 0.030 |
Why?
|
| Community Health Centers | 1 | 2016 | 57 | 0.030 |
Why?
|
| Mutation | 1 | 2020 | 1177 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2020 | 1546 | 0.030 |
Why?
|
| Information Dissemination | 1 | 2015 | 66 | 0.030 |
Why?
|
| Pitch Perception | 1 | 2014 | 2 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2015 | 142 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2009 | 1604 | 0.030 |
Why?
|
| Temporal Lobe | 1 | 2014 | 26 | 0.030 |
Why?
|
| Obesity | 1 | 2022 | 1151 | 0.030 |
Why?
|
| Algorithms | 1 | 2017 | 509 | 0.030 |
Why?
|
| Motor Cortex | 1 | 2014 | 54 | 0.030 |
Why?
|
| Brain Mapping | 1 | 2014 | 137 | 0.020 |
Why?
|
| Nerve Net | 1 | 2014 | 101 | 0.020 |
Why?
|
| Prefrontal Cortex | 1 | 2014 | 164 | 0.020 |
Why?
|
| Guidelines as Topic | 1 | 2012 | 56 | 0.020 |
Why?
|
| Relaxation Therapy | 1 | 2011 | 3 | 0.020 |
Why?
|
| Integrative Medicine | 1 | 2011 | 8 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 2011 | 62 | 0.020 |
Why?
|
| Photic Stimulation | 1 | 2011 | 125 | 0.020 |
Why?
|
| Castration | 1 | 2010 | 34 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2012 | 233 | 0.020 |
Why?
|
| Austria | 1 | 2010 | 5 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2014 | 587 | 0.020 |
Why?
|
| Focus Groups | 1 | 2012 | 423 | 0.020 |
Why?
|
| Physicians | 1 | 2012 | 188 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2012 | 760 | 0.020 |
Why?
|
| Colorectal Neoplasms | 1 | 2015 | 512 | 0.020 |
Why?
|
| Cognition Disorders | 1 | 2011 | 243 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2010 | 237 | 0.020 |
Why?
|
| Bothrops | 1 | 2009 | 1 | 0.020 |
Why?
|
| Antivenins | 1 | 2009 | 4 | 0.020 |
Why?
|
| Penicillins | 1 | 2009 | 10 | 0.020 |
Why?
|
| Crotalus | 1 | 2009 | 4 | 0.020 |
Why?
|
| Rodentia | 1 | 2009 | 47 | 0.020 |
Why?
|
| Doxycycline | 1 | 2009 | 32 | 0.020 |
Why?
|
| Immunologic Factors | 1 | 2009 | 51 | 0.020 |
Why?
|
| Urban Health | 1 | 2009 | 101 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2010 | 452 | 0.020 |
Why?
|
| Social Support | 1 | 2011 | 445 | 0.020 |
Why?
|
| Poverty Areas | 1 | 2008 | 47 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2008 | 90 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2009 | 223 | 0.020 |
Why?
|
| Drug Costs | 1 | 2007 | 35 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2008 | 490 | 0.020 |
Why?
|
| Reference Values | 1 | 2006 | 211 | 0.010 |
Why?
|
| Nutrition Surveys | 1 | 2007 | 263 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2007 | 587 | 0.010 |
Why?
|
| Carbohydrate Dehydrogenases | 1 | 2005 | 12 | 0.010 |
Why?
|
| Exercise | 1 | 2011 | 692 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2006 | 638 | 0.010 |
Why?
|
| Kidney Diseases | 1 | 2006 | 172 | 0.010 |
Why?
|
| Medicare | 1 | 2007 | 332 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2005 | 368 | 0.010 |
Why?
|
| Mexico | 1 | 2005 | 298 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2005 | 934 | 0.010 |
Why?
|